| Karoon Energy Ltd (KAR) ORDINARY FULLY PAID |
Energy |
$1,393 |
Capital returns policy and launch of on-market buy back
|
25 Jul 2024 9:36AM |
$1.795 |
$1.900 |
risen by
5.85%
|
|
KAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Karoon Energy Ltd. revised its capital allocation framework and announced a US$25 million on-market buyback.
- The new capital allocation policy includes investing in existing assets, pursuing growth opportunities, and delivering annual capital returns to shareholders.
- Karoon aims to return 20-40% of underlying NPAT to shareholders via dividends or share buybacks, depending on market conditions and Board approval.
- The buyback program is expected to commence following the announcement of quarterly results, with completion targeted by 31 December 2024.
- Board Chairman Peter Botten highlighted the company's transformation over the past four years and emphasized the balance between rewarding shareholders and maintaining a robust balance sheet.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Peninsula Energy Limited (PEN) ORDINARY FULLY PAID |
Energy |
$99 |
Quarterly Cashflow Report
|
25 Jul 2024 9:35AM |
$0.105 |
$0.620 |
risen by
490.48%
|
|
PEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Peninsula Energy Limited released a quarterly cashflow report for the quarter ended 30 June 2024.
- The company reported receipts from customers totaling $11,866,000 for the year to date.
- Payments included $723,000 for staff costs and $1,687,000 for administration and corporate costs.
- Development costs for the Lance Project amounted to $14,087,000 during the current quarter.
- The company generated $70,968,000 in proceeds from issuing equity securities, offset by $4,826,000 in related transaction costs.
- Net cash from financing activities was $66,140,000.
- Cash and cash equivalents at the end of the period were $99,854,000.
- The report was authorized for release by the Board of Directors on 25 July 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genex Power Limited (GNX) ORDINARY FULLY PAID |
Utilities |
- |
Appendix 3Y - Teresa Dyson
|
25 Jul 2024 9:35AM |
$0.275 |
$0.275 |
fallen by
0%
|
|
| Peninsula Energy Limited (PEN) ORDINARY FULLY PAID |
Energy |
$99 |
Quarterly Activities Report
|
25 Jul 2024 9:35AM |
$0.105 |
$0.620 |
risen by
490.48%
|
|
PEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Equity raising to fund operations through to mid-2025.
- Engineering, Procurement, and Construction (EPC) contractor mobilized for the Ross CPP expansion.
- Construction and procurement activities progressing as scheduled for a production restart in late 2024.
- Key workstreams for new production wellfield Mine Unit 3 on track for uranium recovery in late 2024.
- 118 production wells drilled during the quarter.
- Mineral Resource Estimate (MRE) expanded Lance Projects to 58.0 Mlbs U3O8.
- Life-of-Mine study area MRE increased by 19.6% to 26.2 Mlbs U3O8.
- A$106 million Equity Raising completed.
- Proceeds from the equity raising expected to fund operations to sustainable free cash flow in Q3 2025.
- Appointment of Mr. David Coyne as Non-Executive Director.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$131 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
25 Jul 2024 9:34AM |
$0.170 |
$0.110 |
fallen by
35.29%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Arovella Therapeutics has $12.7 million in cash as of June 30, 2024.
- Funds are sufficient to obtain preliminary data in a planned first-in-human clinical trial for ALA-101.
- Arovella plans to achieve several milestones within the next 12 months, including manufacturing clinical batches of ALA-101, securing regulatory acceptance for a phase 1 clinical trial, commencing the trial, and presenting preclinical proof-of-concept data for other programs.
- Arovella completed the development of a clinic-ready manufacturing process for ALA-101 and the CAR-iNKT cell platform.
- The new manufacturing process is suitable for large-scale production and meets regulatory standards for first-in-human clinical trials.
- Arovella completed a $12.5 million capital raise, supported by institutional and sophisticated investors, to fund the Phase 1 clinical trial and strengthen its cell therapy pipeline.
- The company appointed Professor Gianpietro Dotti to its Scientific Advisory Board.
- Arovella has a robust pipeline and diverse cell therapy products in development, including solid tumor treatments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Black Canyon Limited (BCA) ORDINARY FULLY PAID |
Materials |
$31 |
Trading Halt
|
25 Jul 2024 9:33AM |
$0.080 |
$0.240 |
risen by
200%
|
|
BCA - Price-sensitive ASX Announcement
Full Release
Key Points
- Black Canyon Limited (BCA) requested a trading halt.
- The request was made pending an announcement of a proposed capital raise.
- The trading halt commenced on 25 July 2024.
- The halt will last until 29 July 2024 or until the announcement is made.
- ASX Compliance issued the halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arafura Rare Earths Ltd (ARU) ORDINARY FULLY PAID |
Materials |
$567 |
Completion of A$20m institutional placement
|
25 Jul 2024 9:32AM |
$0.190 |
$0.230 |
risen by
21.05%
|
|
ARU - Price-sensitive ASX Announcement
Full Release
Key Points
- Firm commitments for a fully underwritten A$20 million institutional placement
- Placement price set at A$0.16 per share
- 125 million new shares to be issued across two tranches
- Tranche 1 raises A$14.2 million and does not require shareholder approval
- Tranche 2 raises A$5.8 million subject to shareholder approval
- Shareholder meeting (EGM) to be held on 4 September 2024
- Trading on ASX to resume on 25 July 2024
- Settlement dates: 31 July 2024 for Tranche 1 and 6 September 2024 for Tranche 2
- Arafura also announces a Share Purchase Plan (SPP) to raise A$7 million
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Buxton Resources Limited (BUX) ORDINARY FULLY PAID |
Materials |
$16 |
84.6m of mineralisation intersected at Graphite Bull Project
|
25 Jul 2024 9:32AM |
$0.080 |
$0.047 |
fallen by
41.25%
|
|
BUX - Price-sensitive ASX Announcement
Full Release
Key Points
- 84.6 m of graphitic mineralisation intersected in drill hole GB006DD.
- The Main Zone intersection is approximately 240 meters down-dip from the existing 2014 resource.
- Mineralisation remains open at depth and along strike, confirming the effectiveness of EM modeling.
- Current drilling continues with the commencement of diamond drill hole GB007DD, 600 meters east.
- Buxton Resources aims to increase the Graphite Bull project's resource confidence and size due to growing global demand for graphite in lithium-ion batteries.
- GB006DD includes 50.35 meters of visually estimated graphitic mineralisation in a 52.2-meter-thick zone.
- Buxton Resources acquired the Graphite Bull project in 2012.
- The project currently has a JORC 2012 compliant inferred resource of 4 Mt @ 16.2% TGC.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$19 |
Notification regarding unquoted securities - LIT
|
25 Jul 2024 9:32AM |
$0.022 |
$0.011 |
fallen by
50%
|
|
| Mayne Pharma Group Limited (MYX) ORDINARY FULLY PAID |
Health Care |
$408 |
MYX announces patent lawsuit against Sun Pharmaceutical
|
25 Jul 2024 9:32AM |
$4.520 |
$5.020 |
risen by
11.06%
|
|
| Karoon Energy Ltd (KAR) ORDINARY FULLY PAID |
Energy |
$1,393 |
2024 Second Quarter Report
|
25 Jul 2024 9:30AM |
$1.795 |
$1.900 |
risen by
5.85%
|
|
KAR - Price-sensitive ASX Announcement
Full Release
Key Points
- 2024 second quarter production dropped to 2.14 MMboe, 27% lower due to Baúna maintenance
- Sales revenue increased by 8% to US$212.8 million
- Capital returns policy finalized with 20-40% of NPAT to shareholders
- US$25 million share buyback launched due to undervaluation of shares
- Who Dat East well discovered hydrocarbons, suspended for future
- Who Dat South well drilling expected in third quarter of 2024
- Two safety incidents and a Tier 2 Process Safety Event reported
- Maintained CY24 production and cost guidance, projecting DD&A of US$16 - 17 per boe
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genex Power Limited (GNX) ORDINARY FULLY PAID |
Utilities |
- |
Appendix 3Y - Ralph Craven
|
25 Jul 2024 9:30AM |
$0.275 |
$0.275 |
fallen by
0%
|
|
| Genex Power Limited (GNX) ORDINARY FULLY PAID |
Utilities |
- |
Appendix 3Y - Ben Guo
|
25 Jul 2024 9:30AM |
$0.275 |
$0.275 |
fallen by
0%
|
|
| Dragon Mountain Gold Limited (DMG) ORDINARY FULLY PAID |
Materials |
$2 |
Drill Program Commences at Avalon
|
25 Jul 2024 9:29AM |
$0.007 |
$0.004 |
fallen by
42.86%
|
|
| PolarX Limited (PXX) ORDINARY FULLY PAID |
Materials |
$24 |
Trading Halt
|
25 Jul 2024 9:29AM |
$0.013 |
$0.010 |
fallen by
23.08%
|
|
PXX - Price-sensitive ASX Announcement
Full Release
Key Points
- Request for immediate trading halt by PolarX Limited.
- Trading halt due to pending announcement regarding capital raising.
- Halt to continue until 29 July 2024 or until announcement release.
- Compliance with ASX Listing Rule 17.1.
- No known reasons against granting the halt or additional necessary market information.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amaero Ltd (3DA) ORDINARY FULLY PAID |
Industrials |
$339 |
Quarterly Activities Report and Appendix 4C
|
25 Jul 2024 9:29AM |
$0.405 |
$0.490 |
risen by
20.99%
|
|
3DA - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful settlement of A$20 million institutional placement led by Fidelity International.
- Completion and acceptance of atomiser commissioning ahead of schedule.
- Appointment of former U.S. National Security Advisor H.R. McMaster as Special Advisor.
- Proprietary modifications to the atomisation process commenced.
- Net operating cash outflows of AU$4.56 million for the quarter.
- Net increase in cash and cash equivalents to AU$11.99 million.
- Focus on becoming the largest U.S. domestic supplier of refractory and specialty alloy powder.
- Strategic steps towards improving resiliency in U.S. domestic production of specialty powders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$22 |
Proposed issue of securities - OSL
|
25 Jul 2024 9:28AM |
$0.009 |
$1.180 |
risen by
13,011.11%
|
|
| Pacific Smiles Group Limited (PSQ) ORDINARY FULLY PAID |
Health Care |
$266 |
Dr Alison Hughes intends to vote in favour of the NDC Scheme
|
25 Jul 2024 9:28AM |
$1.820 |
$1.645 |
fallen by
9.62%
|
|
PSQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Dr Alison Hughes intends to vote in favour of the NDC Scheme.
- Dr Alison Hughes represents approximately 9.90% of the Pacific Smiles Shares.
- The Scheme involves NDC BidCo Pty Ltd acquiring 100% of the shares in Pacific Smiles.
- The acquisition is proposed via a scheme of arrangement for cash consideration of $1.911 per share.
- The announcement encourages shareholders to vote on the Scheme to determine its proceeding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noronex Limited (NRX) ORDINARY FULLY PAID |
Materials |
$7 |
NRX Takes 100% Control of Snowball East & Dordabis Update
|
25 Jul 2024 9:27AM |
$0.014 |
$0.013 |
fallen by
7.14%
|
|
NRX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noronex takes 100% control of the Snowball Copper Project in Namibia.
- Agreement with former farm-in partners to discontinue Snowball Farm-In.
- Noronex gains 100% ownership of Eastern Licence EPL 7415.
- Over A$1.5M spent in exploration of Snowball Project.
- Prospective targets in Snowball East to be prioritized for further exploration.
- Part payment of A$0.4M received for Dordabis sale.
- Final payment date for Dordabis sale extended.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Javelin Minerals Limited (JAV) ORDINARY FULLY PAID |
Materials |
$13 |
Notification regarding unquoted securities - JAV
|
25 Jul 2024 9:27AM |
$0.002 |
$0.002 |
risen by
33.33%
|
|
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$15 |
Quarterly Activities Report and Appendix 4C
|
25 Jul 2024 9:27AM |
$0.025 |
$0.020 |
fallen by
20%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Approximately 400k HIV self-test units sold in Q4.
- Australian Government announced two years of funding for HIV self-test procurement.
- Newfoundland launched Atomo HIV Self-Test in UK Boots stores.
- Development programs with the Burnet Institute continued.
- Reported Q4 revenue of $1.64 million and YTD revenue of $4.09 million.
- Cash receipts from customers were $1.08 million.
- Ended the quarter debt-free with $3.69 million in cash.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bellevue Gold Limited (BGL) ORDINARY FULLY PAID |
Materials |
$1,332 |
Trading Halt
|
25 Jul 2024 9:26AM |
$1.830 |
$0.903 |
fallen by
50.68%
|
|
BGL - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Bellevue Gold Limited.
- Effective immediately from 25 July 2024.
- Pending announcement regarding a material capital raising.
- Securities to remain in halt until 29 July 2024 or announcement release.
- Company is not aware of any reason why the halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Duxton Farms Ltd (DBF) ORDINARY FULLY PAID |
Consumer Staple |
$42 |
Update - Notification of buy-back - DBF
|
25 Jul 2024 9:26AM |
$1.555 |
$1.020 |
fallen by
34.41%
|
|
| Metrics Master Income Trust (MXT) ORDINARY UNITS FULLY PAID |
Financials |
$2,505 |
Dividend/Distribution - MXT
|
25 Jul 2024 9:25AM |
$2.080 |
$2.050 |
fallen by
1.44%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$22 |
Proposed issue of securities - OSL
|
25 Jul 2024 9:25AM |
$0.009 |
$1.180 |
risen by
13,011.11%
|
|
Call 1300 880 160
Start a chat
Schedule a call
